From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.
Fadi Fakhouri, MD, PhD
Advertisement
Fadi Fakhouri, MD, PhD, is a professor of nephrology at CHUV Lausanne, Switzerland.
Articles by Fadi Fakhouri, MD, PhD
52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5